Search results for "polycystic ovary syndrome."

showing 10 items of 62 documents

Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance.

2015

PURPOSE: Insulin resistance and compensatory hyperinsulinism are the predominant metabolic defects in polycystic ovary syndrome (PCOS). However, hyperinsulinism, as well as being compensatory, can also express a condition of reduced insulin clearance. Our aim was to evaluate the differences in insulin action and metabolism between women with PCOS (with normal glucose tolerance) and age- and BMI-matched women with prediabetes (without hyperandrogenism and ovulatory disorders). METHODS: 22 women with PCOS and 21 age/BMI-matched women with prediabetes were subjected to a Hyperinsulinemic-euglycemic clamp and an Oral Glucose tolerance Test (OGTT). Insulin sensitivity was assessed by the glucose…

Adultmedicine.medical_specialtyendocrine system diseasesAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSettore MED/13 - EndocrinologiaPrediabetic StateYoung AdultEndocrinologyInsulin resistanceInternal medicineHyperinsulinismmedicineHumansInsulinPrediabetesbusiness.industryPolycystic ovary syndrome (PCOS)InsulinHyperandrogenismnutritional and metabolic diseasesGlucose clamp techniquemedicine.diseasePolycystic ovaryEndocrinologypolycystic ovary syndromeGlucose Clamp TechniqueFemaleInsulin ResistancebusinessHyperinsulinismPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct

Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes

2007

Background: Serum DHEAS has been found to be elevated in some women with polycystic ovary syndrome (PCOS). We wished to determine whether this prevalence is different in women with androgen excess who have different phenotypes and to correlate these findings with various cardiovascular and metabolic parameters. Methods: Two hundred and thirty-eight young hyperandrogenic women categorized into various diagnostic groups were evaluated for elevations in serum DHEAS, testosterone, glucose, insulin, quantitative insulin-sensitivity check index (QUICKI), cholesterol, HDL-C, LDL-C, triglycerides and C-reactive protein (CRP). Data were stratified based on elevations in DHEAS. Results: Serum DHEAS w…

Adultmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAndrogen Excesschemistry.chemical_compoundEndocrinologyInternal medicinePrevalenceHumansInsulinMedicineTestosteroneTestosteronebusiness.industryCholesterolInsulinPolycystic ovary syndrome (PCOS)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePhenotypePolycystic ovaryPhenotypeEndocrinologychemistryAdrenal CortexAndrogensFemaleHyperandrogenismbusinessPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Uterine effects of metformin administration in anovulatory women with polycystic ovary sindrome

2006

Background Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. Methods Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whil…

Adultmedicine.medical_specialtyendocrine system diseasesPhysiologymedia_common.quotation_subjectUterusEndometriumFertility AgentsAnovulationEndometriumanovulation; endometrium; metforminMenstruation-Inducing AgentUltrasoundmedicinePCOSHumansOvulationFertility Agentmedia_commonGynecologyMenstruation-Inducing Agentsbusiness.industryRehabilitationUterusanovulation endometrium metformin PCOS ultrasoundnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsMetforminMetforminPregnancy ratemedicine.anatomical_structureUteruReproductive MedicineIn uteroRegional Blood FlowFemalebusinessmedicine.drugAnovulationHumanPolycystic Ovary SyndromeDevelopmental Biology
researchProduct

Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression

2019

Abstract Background A limited number of publications have assessed the prevalence of hypertension (HTN) in polycystic ovary syndrome (PCOS) patients with inconclusive results. Since in general populations the occurrence of hypertension is related to age per se, we investigated the prevalence (P) / relative risk (RR) of HTN in pooled patients with PCOS, vs control population among reproductive age women with PCOS, compared to menopause/aging patients. Methods PubMed, Scopus, ScienceDirect, web of science, and Google scholar were systematically searched for retrieving observational studies published from inception to April 2019 investigating the HTN in patients with PCOS. The primary outcome …

Adultmedicine.medical_specialtylcsh:QH471-489endocrine system diseasesPopulationReproductive medicineComorbidityReview:Medisinske Fag: 700::Klinisk medisinske fag: 750::Endokrinologi: 774 [VDP]lcsh:Gynecology and obstetricsRisk AssessmentEndocrinologyRisk FactorsInternal medicinemedicinePrevalencelcsh:ReproductionHumansMeta-regressioncardiovascular diseaseseducationlcsh:RG1-991Polycystic ovary syndromeeducation.field_of_studybusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsMenopauseRelative riskMeta-analysisReproductive MedicineMeta-analysisRelative riskHypertensionObservational studyFemalebusinessDevelopmental Biology
researchProduct

Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study

2006

Background Previous data on the efficacy of clomiphene citrate, the most commonly used drug for treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS), have shown a discrepancy between ovulation and pregnancy rates. In the present subanalysis (of a larger previously published randomized controlled trial), the effect of clomiphene citrate on several ultrasonographic markers of uterine receptivity in PCOS patients who ovulated under treatment was studied. Methods Thirty-three PCOS women who ovulated under 150 mg daily clomiphene citrate and 33 healthy controls were studied. Uterine, subendometrial and endometrial blood flows, endometrial thickness and pattern were …

Adultmedicine.medical_specialtymedia_common.quotation_subjectEarly Pregnancy LossUterusanovulation; clomiphene citrate; Doppler; PCOS; velocimetryBiologyClomiphenelaw.inventionAnovulationRandomized controlled trialPregnancyReference ValueslawClomifeneclomiphene citratemedicinePCOSHumansOvulationUltrasonographymedia_commonGynecologyPregnancyvelocimetryObstetricsRehabilitationEstrogen AntagonistsPregnancy OutcomeDopplerObstetrics and GynecologyGenitalia Femalemedicine.diseasePolycystic ovaryTreatment Outcomemedicine.anatomical_structureReproductive Medicinepolycystic ovary syndromeanovulationFemalemedicine.drug
researchProduct

No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.

2013

Context: Women with type 1 diabetes mellitus (DM1) have a higher prevalence of polycystic ovary syndrome (PCOS) than the general population. Objective: The aim of this study was to clarify, in DM1 women with PCOS(PCOS-DM1), the influence of insulin therapy and glycemic control and evaluate the hormonal and phenotypic differences with age-matched and body mass index (BMI)-matched women with PCOS without diabetes. Design, Setting, and Patients: We evaluated 103 DM1 women with and without PCOS treated with intensive insulin therapy; 38 age-matched and BMI-matched women with PCOS without diabetes were compared in a cross-sectional study. Outcome Measurements: Clinical, anthropometric, and metab…

Adultmusculoskeletal diseasesPCOS Type 1 Diabetescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectClinical BiochemistryPopulationContext (language use)BiochemistryBody Mass IndexSettore MED/13 - EndocrinologiaYoung AdultEndocrinologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationReproductive HistoryMenstrual cyclemedia_commoneducation.field_of_studyType 1 diabetesbusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)nutritional and metabolic diseasesmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsCross-Sectional StudiesDiabetes Mellitus Type 1PhenotypeEndocrinologyCase-Control StudiesFemalebusinessBody mass indexPolycystic Ovary Syndrome
researchProduct

Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women

2008

Summary Objective  The aim of the present study was to determine if the favourable cardiopulmonary and metabolic benefits induced by exercise training (ET) programme are maintained after its cessation. Patients  Thirty-two young overweight polycystic ovary syndrome (PCOS) women matched for age and body mass index (BMI) with other 32 PCOS patients was enrolled. The first group [PCOS-T (trained)] underwent 24-week ET programme, whereas the second [PCOS-DT (detrained)] underwent 12-week ET programme followed by 12-week detraining period. Methods  At baseline, after 12- and 24-week follow-up, all PCOS women were studied for their hormonal (ovarian and adrenal androgens), metabolic (glucose and …

Blood GlucoseSettore MED/09 - Medicina Internaendocrine system diseasescardiopulmonary effectsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOverweightSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyInsulinmedicine.diagnostic_testVO2 maxPCOS womenPolycystic ovaryfemale genital diseases and pregnancy complicationsRespiratory Function TestsCholesterolHeart Function Testspolicystic ovary syndromeFemalemedicine.symptomPhysical exercise training cardiovascular function pulmonary function PCOS hyperandrogenism insulin resistanceSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotoriePolycystic Ovary Syndromemedicine.medical_specialtyexercise training programmeLipoproteinsPhysical exerciseOxygen ConsumptionInternal medicinemedicineHumansExercise physiologyExerciseTriglyceridescardiopulmonary functionbusiness.industryInsulinMetabolic effects; cardiopulmonary effects; exercise training programme; PCOS womennutritional and metabolic diseasesOverweightCardiovascular riskSettore MED/11 - Malattie Dell'Apparato CardiovascolareMetabolic effectsEndocrinologystructured exercise training programmebusinessLipid profileBody mass index
researchProduct

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproteron…

2017

Abstract Background Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3 months to 1 year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. Materials and methods PubMed, Scopus, Google Scholar and ScienceDirect databases (2001–2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PC…

Blood Glucosemedicine.medical_specialtyTime Factorsmedicine.drug_classEndocrinology Diabetes and MetabolismBlood lipidsBlood Pressure030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDesogestrelInternal medicinemedicineHumansInsulinCyproterone AcetateClinical Trials as Topic030219 obstetrics & reproductive medicinebusiness.industryBody WeightCyproterone acetateDrospirenoneLipid Metabolismmedicine.diseasePolycystic ovaryEndocrinologychemistryMetabolomeFemaleProgestinsbusinessProgestinBody mass indexContraceptives OralPolycystic Ovary Syndromemedicine.drugMetabolism
researchProduct

Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome

2003

To determine the prevalence of insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) using baseline fasting blood measurements of glucose and insulin. Prospective clinical study. Academic endocrinology unit in Palermo, Italy. Two hundred and sixty-seven women with PCOS, consecutively evaluated, and 50 consecutively selected ovulating controls. Fasting blood was obtained for glucose and insulin measurements from all women. For 60 women with PCOS and 20 controls an insulin tolerance test (ITT) was also performed. Assessment of normal and abnormal values for fasting insulin, glucose/insulin ratio, and the calculated indices of the homeostasis model assessment (HOMA), quantitat…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentFasting insulinInsulin resistanceReference ValuesInternal medicinemedicineHomeostasisHumansInsulinPancreatic hormoneRetrospective Studiesbusiness.industryInsulinQuantitative insulin sensitivity check indexInsulin tolerance testInsulin Resistance Fasting physiology Insulin blood Polycystic Ovary SyndromeObstetrics and GynecologyFastingmedicine.diseasePolycystic ovaryEndocrinologyReproductive MedicineFemaleInsulin ResistancebusinessBody mass indexPolycystic Ovary Syndrome
researchProduct

Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guidelin…

2006

OBJECTIVE: The Androgen Excess Society (AES) charged a task force to review all available data and recommend an evidence-based definition for polycystic ovary syndrome (PCOS), whether already in use or not, to guide clinical diagnosis and future research. PARTICIPANTS: Participants included expert investigators in the field. EVIDENCE: Based on a systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, we tried to identify studies evaluating the epidemiology or phenotypic aspects of PCOS. CONSENSUS PROCESS: The task force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and critiqued by …

ConsensusAndrogensHumansFemaleGuidelines as TopicHyperandrogenismSocieties Medicalpolycystic ovary syndrome cardiovascular risk insulin resistancePolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct